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The EU Clinical Trials Directive came into force on 1 May 2004
and has changed the face of Clinical Trials of investigational
medicinal products in the UK. An enthusiastic registrar or
consultant who comes up with an idea for a therapeutic
intervention now needs to comply with a complex and demanding
set of legal, ethical and regulatory requirements, contravention of
which may lead to criminal proceedings. The aim of this review
was to detail the relevant procedures and regulations and to
provide a ‘user-friendly’ guide to obstetricians and gynaecologists
wishing to conduct a clinical trial of an investigational medicinal
product. Sources of further information are listed.
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Introduction
On 1 May 2004, new regulations cameinto force across Europe
to better protect the rights, safety and wellbeing of patients
participatinginclinicaltrialsofinvestigationalmedicalproducts
(IMPs). This EU Clinical Trial Directive 2001/20/EU1 relates to
the implementation of Good Clinical Practice (GCP) in the
conduct of clinical trials of IMPs. This has been incorporated
into UK law by the Medicines for Human Use (Clinical Trials)
Regulations2004.2TheEUhasrecently(July2006)issuedguid-
anceonGCPissues.3Anyonedesigningorconductingaclinical
trial of an IMP has to now comply with these regulations.
The Medicines and Healthcare products Regulatory Agency
(MHRA) provides a guide to what is a medicinal product.4 An
investigational medicinal product is a pharmaceutical form of
an active substance or placebo being tested, or to be tested, as
areferenceinaclinicaltrial.Forexample,oxygenthatisusedfor
respiratory support is considered as a medicinal product by the
MHRA.Presently,onlytrialsinvolvingIMPsfallunderthescope
of the directive and are the focus of this review. Trials not
involvingIMPs(e.g.trialsofsurgicalinterventions)areexcluded
from this review, although the expectation of the stakeholders
(sponsors,ethicscommittees, researchanddevelopment(R&D)
ofﬁces, the medical research community and participants) is
thattheywouldbeconductedtothesamestandard,sincepatient
safety and scientiﬁc robustness is important in all trials.
‘GCP’ is a set of rules and regulations5 by which clinical
trials must be conducted. GCP was developed by regulatory
authorities from USA, Europe and Japan at the International
Conference of Harmonisation in 1997, and the main principle
is that ‘the rights, safety and wellbeing of the trial subjects are
the most important considerations and should prevail over
the interests of society’.
It is therefore imperative that anyone who is involved in
a clinical trial is not only qualiﬁed for the purpose but also
trained in GCP. The UK Clinical Research Network, launched
in February 2005, has training as an important part of its
remit (www.ukcrn.org.uk/index/training).6
The deﬁnition of a clinical trial
A ‘clinical trial’ is speciﬁcally deﬁned by the EU Directive as
any investigation in human subjects intended:
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products.
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3 To study absorption, distribution, metabolism and excre-
tion of one or more such products with the object of ascer-
taining the safety or efﬁcacy of those products.
The MHRA (the ‘Competent Authority’ for the UK) have
released an algorithm to establish whether a study qualiﬁes as
aclinicaltrialundertheEUDirective.7Ifitdoes,thenaSponsor
must be identiﬁed and a EudraCT number must be obtained,
followed by authorisation from MHRA and approval by a
Research Ethics Committee (REC) and the NHS R&D depart-




A protocol is a full description of the aims and methods of the
clinical trial. Under the UK Regulations, the protocol must
now include the information listed in the guideline for GCP.5
The regulations require that the clinical trial has to be con-
ducted in accordance with the protocol. The Sponsor must
notify any ‘substantial amendment’ to the protocol both to
the MHRA and to the main REC for approval. A user-friendly
web-based protocol development tool, focusing on pragmatic
trials, has been written by the EU funded Pragmatic Random-
ized Controlled Trials in HealthCare (PRACTIHC) research
group and is available free at www.practihc.org.
Finding a Sponsor
Since 1 May 2004, it is illegal to start a clinical trial without
a Sponsor, deﬁned by the EU Directive as an individual, com-
pany, institution or an organisation which takes responsibility
for the initiation, management and/or ﬁnancing of a clinical
trial. A very useful guide on Sponsor responsibilities is given
ontheMedicalResearchCouncil/ Department ofHealth (MRC/
DOH) generated Clinical Trials Tool Kit (www.ct-toolkit.ac.uk,
under Planning a New Trial > Identifying a Sponsor).8
For commercially funded trials, the Sponsor will invariably be
the drug company. For publicly funded trials (of, for example,
head to head comparisons of licensed drugs), the funder (often
a government agency or a charity) usually look to the employer
of the Chief Investigator—typically the NHS or a University, or
both—to be the Sponsor.9 Although the Chief Investigator can
act as Sponsor, their employer is much better placed to cover the
risks in a clinical trial through their institutional indemnity and
insurance policies, a key aspect to gaining ﬁnancial approval for
the study. It is important to secure sponsorsearly in the planning
process and have written, legally binding contracts detailing the
responsibilities that have been agreed between the partners.
The R&D department of either the University or the NHS trust
can give guidance on regulatory requirements and instigate a
risk assessment of the study. The NHS R&D Forum10 (www.
rdforum.nhs.uk) gives general information about the roles and
functions of NHS R&D departments.
Getting authorisations (MHRA, Ethics and R&D)
MHRA approval
The European Directive requires the Sponsor to obtain
authorisation from the Licensing Authority of the Member
State in which it is planned to conduct the trial(in the UK, the
MHRA). This is facilitated at a ‘Sponsor interface’, located at
eudract.emea.europa.eu, where a request for authorisation
consists of the application form, supporting information
(including protocol) and the applicable fee. The site also
issues an obligatory EudraCT number uniquely identifying
the trial. The MHRA has 30 days to object to the trial and
give the grounds for nonacceptance (for full details, see
http://www.mhra.gov.uk, under How we regulate > Medi-
cines > Licensing of medicines > Clinical trials > How to
submit a clinical trial application).
Ethics approval
All research in the NHS must be approved by a Department of
Health recognised REC. Detailed information and pro formas
are available on the Central Ofﬁce for Research Ethics
Committees (COREC) website (www.corec.org.uk). The ethics
committee will balance risks to patients against expected ben-
eﬁt and will also review conﬁdentiality and consent issues.
Advice from an experienced investigator is invaluable in pre-
paring an ethics application. Under the EU Directive and the
Clinical Trials Regulations, a REC must give an opinion on
a clinical trial within 60 days of receipt of a valid application
and should reach one of four possible decisions: ‘Final
opinion’—favourable or unfavourable; ‘Provisional opinion’
(with further information or revision required) or ‘No opin-
ion’ (a referee needs to be consulted before an opinion can be
given).
R&D approval
The relevant NHS R&D department must approve trial com-
mencement at a local site, having assessed whether adequate
provision has been made for the costs of NHS staff and con-
sumables in the conduct of the study on NHS premises. Since
January 2007, the R&D application form has been merged
with part C of the REC form.
Trial registration
Trials that begin enrolment of patients after 1 July 2005 must
register in a recognised trials registry at or before the onset
of enrolment to be considered for publication in most lead-
ing medical journals.11 Registration of trials is seen as
an important safeguard against nonreporting of results.12
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Conduct of a trial
Study documentation
Every clinical trial is legally required to have a Trial Master File
(TMF),containingalltheessentialdocumentationforallstages
of the trial. It permits evaluation of the conduct of the trial and
the quality of data produced.13 The TMF is maintained at the
principal site (Chief Investigator’s ofﬁce or Coordinating Cen-
tre) and should be accessible from all participating sites.
Informed consent
The Chief Investigator has overall responsibility for the con-
sent process. Consent must be informed and voluntary. The
Chief Investigator must ensure that any member of staff who
is involved in the process of obtaining informed consent is
fully informed and trained to obtain it.
Data management
Efﬁcient data management is fundamental to any clinical trial.
If data collected is incorrect or of poor quality, then the anal-
ysis and conclusions may be ﬂawed. Trials need a robust sys-
tem in place to ensure the accuracy and completeness of the
data collected and its storage, increasingly provided by formal
trials support units.
Trial monitoring
The purpose of trial monitoring is to verify that the rights and
wellbeing of human subjects are protected; the trial data are
accurate, complete and veriﬁable from source documents;
and that the conduct of the trial is in compliance with
GCP. Site monitoring, central monitoring and scrutiny by
a Data Monitoring Committee (DMC) can play a part in
monitoring. Often a Sponsor will delegate responsibility for
monitoring to the Chief Investigator.
Site monitoring
A person independent of the site, such as the trial manager,
visits a trial site to check adherence to the protocol, to check
informed consent documentation is complete and to verify
events recorded on case report forms. In commercial trials,
site monitoring tends to be very intensive and costly, as com-
pared with publicly funded trials.14,15
Central monitoring
Central monitoring of data using statistical methods is
increasingly being found useful in large multicentre trials
for identiﬁcation of unusual patterns of data. This allows
scare monitoring resource to be targeted at sites in which
problems may be emerging.
DMC monitoring
A DMC, independent of both Sponsor and investigators, is
usually the only group that would expect to see analyses of the
accumulating data by randomised group (i.e. with the ‘blind’
broken). Its main roles are to ensure that there are no safety
issues why the trial should not continue or that there is such
overwhelming evidence of beneﬁt that to continue the trial
would be unethical. The remit and operation of a DMC is
thoroughly discussed by Grant et al.16
Progress reports
The Chief Investigator must provide annual progress reports
to R&D departments, the MHRA and the Ethics Committee,
and possibly the funders. More frequent reports and meetings
are considered good practice for the trial management group,
comprising the investigators and study personnel.
Pharmacovigilance
Clinical trials are generally designed to show efﬁcacy, but they
also document safety (such as potentially dangerous adverse
effectsofnoveldrugs).An‘adverseevent’isanyuntowardexpe-
rience affecting the health of a person recruited into the trial or
anyclinicallyrelevantandpotentiallyharmfullaboratoryresult.
All trials require systems to report adverse events both rap-
idly (e.g. within a fortnight) and periodically (e.g. annually) in
accordance with the legislations. Importantly, the investigator
has to report any serious adverse event to the Sponsor, and the
Sponsor has to report any suspected unexpected serious
adverse reaction immediately to MHRA (in UK) and to the
ethics committee. Detailed guidance is available on the collec-
tion, veriﬁcation and presentation of adverse events.17
By collecting all safety data on trials in Member States (with
a combined population of over 400 million) into a single
European pharmacovigilance database, it is hoped that early
identiﬁcation of safety signals from clinical trials data will be
possible.18
Quality assurance and quality control systems
Statutory Inspections are systematic and independent exam-
ination of trial processes and documentation to determine
whether the trial was properly conducted, analysed and accu-
rately reported. In the UK, statutory inspections are the
responsibility of the MHRA. In addition to statutory inspec-
tions, funders, sponsors and NHS R&D departments may
want to conduct audits of trial sites.
Publication issues
All trials should be written up and published regardless of
whether the results are positive, negative or inconclusive.19
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to the reader, in a transparent manner, why the study was
undertaken and how it was conducted and analysed. The
CONSORT statement is an important research tool that takes
an evidence-based approach to improve the quality of reports
of randomised trials.20 In addition, there is now a move by the
public funders of research to support an open access model
for publishing. This has potentially signiﬁcant consequences
for the way in which research is published.21
Study closedown and archiving
The protocol should clearly deﬁne the end of a trial, usually
the completion of recruitment and the appropriate follow-up
period. The competent authority (MHRA), ethics committee
and R& D department must be notiﬁed within 90 days of
a trial ending (15 days if it is terminated early, with the
reasons for early termination).
Essential documents must be archived and be accessible
for audit and inspection by regulatory authorities. The EU
Directive requires retention for at least 5 years after trial end
(for nonregulatory submission trials) and for a trial leading
to a product licensing submission, at least 2 years after the
last approval of a marketing application in the EU. In pub-
licly funded trials, researchers are increasingly using reliable
and affordable scanning technology to digitise their key
documents, storing research documents indeﬁnitely at little
continuing cost. However, care needs to be taken to ensure
that such digitised documents are kept in an established data
archive so that they can be migrated, without loss of any
data, from one system to the next as the information tech-
nology changes. In addition, there is an important trend
to make available the raw study data, after an appropriate
time, in publicly accessible data archives, thus allowing the
scientiﬁc community opportunity for further analysis and
research.22
Conclusion
With the new regulations in place, while the trials may
appear very complex to conduct, in a way they are ‘easier’
as the process is now well described with clear guidelines for
every step. However, these processes are time consuming
and have to be followed in logical order. In summary, the
ﬁrst step is to conﬁrm that the trial falls within the scope of
the UK Regulations. If it does, then the trial protocol should
be written and funding sought with the regulations in mind.
A Sponsor must be identiﬁed and a EudraCT number
obtained, followed by authorisation from MHRA and
approval by an Ethics Committee and the NHS R&D depart-
ment. During the conduct of the trial, at least annual prog-
ress reports are required to the stakeholders (including
regulators, ethics, sponsors and funders). Safety reporting
(both rapid and periodic) is key. Continuing monitoring
of the trial to fulﬁl these progress reporting is now obliga-
tory. Keeping accurate trial documentation for all stages
before, during and after the conduct of a trial is important,
and one should be prepared for external inspection of trial
data and processes. Clinical research in the UK is becoming
increasingly network orientated, with the establishing of the
UK Clinical Research Collaboration (www.ukcrc.org).
Although currently there are few formally established clini-
cal networks in obstetrics and gynaecology (with perhaps the
exception of gynaecological oncology), these networks are
beginning to emerge, allied with the Royal College. Investi-
gators wishing to develop a trial of an investigational medic-
inal product should seek the support of such networks and
in addition need to involve an established clinical trials unit
to assist both in gaining funding and in complying with the
existing relevant regulations.
Web resources
www.corec.org.uk/ Central Ofﬁce for Research Ethics Com-
mittees (COREC). All information available for obtaining
ethics approval for NHS related work.
www.ct-toolkit.ac.uk/ Extremely useful for guidance on
practical implantation of EU Directive. Jointly created by
DOH/MRC.
www.emea.europa.eu/ The European Medicines Agency
(EMEA) is a European Agency for evaluation of medicinal
products. Provides access to EudraCT system to apply for
EudraCT number.
www.mhra.gov.uk/ Ofﬁcial site of the Medicines and
Healthcare products Regulatory Agency (MHRA).
www.ich.org/ Ofﬁcial site of the International Conference
on Harmonisation (ICH)
www.amrc.org.uk/ AMRC (Association of Medical
Research Charities) is a membership organisation of the lead-
ing UK charities that fund medical and health research. It was
founded in 1972 and established as a charity in 1987.
www.tmn.ac.uk/ The UK Trial Manger’s Network
(UKTMN) is a forum for those running publicly funded
trials.
www.ukcrc.org/ UK Clinical Research Collaboration
(UKCRC). The UKCRC brings together the key organisations
that shape the clinical research environment in the UK. This
includes the main funding bodies, academia, the NHS regu-
latory bodies, industry and patients
www.practihc.org/ PRACTIHC is an EU funded interna-
tional collaboration to develop open access tools for the
design and conduct of pragmatic healthcare intervention tri-
als, particularly in developing countries. The related Clinical
Trials Simulator (available free at http://www.randomization.
org) allows investigators to explore the properties of various
potential designs.
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